Supplementation With Creatine Monohydrate In Children With Mitochondrial Encephalomyopathies
| 効果 | 減少 |
| 試験方法 | コホート法 |
| 試験期間 | 1-6 ヶ月 |
| 被験者数 | 4 |
| 性別 | 男女 |
| 年齢 | 7-12, 13-17 |
In children with mitochondrial encephalomyopathy (n=4), an unblinded series of controlled case studies found that 100-200 mg/kg/day for at least 3 months improved both physical endurance (30-57% in three patients) and power output (8-17%) relative to baseline. An increase in daily function and quality of life was also reported. These benefits declined to baseline values when creatine supplementation was stopped.
The myopathies in this study were MELAS (n=1), KSS (n=2), and NARP (n=1).
A Randomized, Controlled Trial Of Creatine Monohydrate In Patients With Mitochondrial Cytopathies
| 効果 | 減少 |
| 試験方法 | 二重盲検法 |
| 試験期間 | 2-4 週間 |
| 被験者数 | 7 |
| 性別 | 男女 |
| 年齢 | 18-29, 30-44, 45-64 |
| 体型 | 平均 |
In persons with mitochondrial cytopathies, 10 g/day (5 g twice a day) for 2 weeks followed by 2 g/day for one week increased maximal muscular function as assessed by handgrip strength (11-19%), although VO~2~ max, aerobic function, and fat oxidation during aerobic exercise were unaffected.
Creatine Has No Beneficial Effect On Skeletal Muscle Energy Metabolism In Patients With Single Mitochondrial DNA Deletions: A Placebo-controlled, Double-blind 31P-MRS Crossover Study
| 効果 | なし |
| 試験方法 | 二重盲検法 |
| 試験期間 | 2-4 週間 |
| 被験者数 | 15 |
| 性別 | 男女 |
| 年齢 | 30-44, 45-64 |
In subjects with mitochondrial disorders associated with single gene deletions that affect the muscles around the eyes (CPEO or KSS), 150 mg/kg/day for 6 weeks failed to improve well-being, power output (handgrip strength test), or any other parameter of exercise, relative to placebo.